Abstract
Neutralizing antibody (nAb) levels against ancestral SARS-CoV-2 from BBIBP-CorV or CoronaVac vaccination were similar and decreased with increasing time since vaccination; over half of 12-month post-vaccination subjects were seropositive. Seropositivity and geometric mean concentrations (GMCs) from BBIBP-CorV and CoronaVac six and nine months after vaccination were similar to or slightly lower than in six-month convalescent sera. These real-world data suggest the necessity of six-month booster doses.
Introduction
While the rapid development of COVID-19 vaccines was a global triumph, the long-term durability of protection—particularly for inactivated virus platforms—remains a critical question for public health policy. Most early studies focused on the initial six months post-vaccination. This study addresses a significant data gap by tracking the 12-month trajectory of neutralizing antibodies in over 1,500 individuals vaccinated with China’s widely used BBIBP-CorV and CoronaVac vaccines. Conducted in a population with minimal prior natural infection due to strict "Dynamic COVID-Zero" policies, this research provides a clear view of vaccine-induced immunity decay and its comparison to natural immunity.
Study Design and Methodology
The researchers conducted cross-sectional sero-surveys in Zhejiang and Shanxi provinces, China, throughout 2021. The study included 1,527 healthy adults (aged 18–59) who had completed a two-dose primary series of either BBIBP-CorV or CoronaVac.
Antibody levels were measured using a standard micro-neutralization cytopathic effect (CPE) assay against the ancestral SARS-CoV-2 strain. A key strength of this study was the use of the first WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin, allowing the conversion of raw titers into standardized Geometric Mean Concentrations (GMC) in IU/mL. This standardization facilitates direct comparison with international datasets.
Longitudinal Antibody Dynamics
The study revealed a significant but gradual decline in neutralizing antibodies over the 12-month period. Despite the drop, immunity did not disappear entirely for the majority of participants. At the one-year mark, 53.5% of BBIBP-CorV recipients and 62.5% of CoronaVac recipients remained seropositive (titer > 1:4).
For BBIBP-CorV, GMC fell from a peak of 217.2 IU/mL at one month to 10.9 IU/mL at 12 months. Similarly, CoronaVac GMC dropped from 195.7 IU/mL to 13.4 IU/mL. When compared to natural immunity, the data showed that by 6–9 months post-vaccination, nAb levels were similar to or slightly lower than those found in individuals six months after recovering from COVID-19 (convalescent GMC: 108.9 IU/mL).
Factors Influencing Immune Response
Statistical modeling identified several demographic factors associated with antibody levels:
- Sex: Females generally maintained higher antibody levels and exhibited slower decay rates compared to males.
- Age: Within the 18–59 age bracket, older individuals (50–59 years) showed significantly lower GMCs than the 18–29 age group, suggesting increased vulnerability even before reaching traditional "elderly" status.
- Standardization: The use of IU/mL provides a universal metric, essential for establishing future "correlates of protection."
Conclusion and Policy Implications
The significant decline in antibody titers by the six-month mark—representing approximately an 80% decrease from peak levels—provides a strong scientific rationale for the administration of booster doses at six-month intervals.
While the study provides robust data on humoral immunity against the ancestral strain, it has limitations. It did not account for immune evasion by variants like Omicron, nor did it measure T-cell responses, which are vital for preventing severe disease. Furthermore, the study population was limited to adults under 60, leaving questions about the highest-risk elderly populations. Nonetheless, these real-world findings are crucial for optimizing global vaccination strategies.
Summary updated